ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.

ARCT Arcturus Therapeutics Holdings Inc

23.69
-1.18 (-4.74%)
Last Updated: 04:19:06
Delayed by 15 minutes
Share Name Share Symbol Market Stock Type
Arcturus Therapeutics Holdings Inc ARCT NASDAQ Common Stock
  Price Change Price Change % Share Price Last Trade
-1.18 -4.74% 23.69 04:19:06
Open Price Low Price High Price Close Price Previous Close
24.87 23.56 25.30 24.87
more quote information »

Recent News

Date Time Source Heading
05/12/202300:30BWArcturus Therapeutics to Present at the 42nd Annual J.P...
29/11/202300:05PRNUSJapan's Ministry of Health, Labour and Welfare Approves CSL..
29/11/202300:00BWJapan's Ministry of Health, Labour and Welfare Approves CSL..
28/11/202301:13DJNArcturus Therapeutics Gets FDA Orphan Designation for..
28/11/202300:30BWArcturus Therapeutics Receives Orphan Drug Designation from..
16/11/202300:51IHMARKETNEWSKeep An Eye Out: Pre-Market Movers And Analyst..
15/11/202308:10EDGAR2Form 8-K - Current report
15/11/202308:01BWArcturus Therapeutics Announces Third Quarter 2023 Financial..
26/10/202307:01BWArcturus Therapeutics to Report Third Quarter Financial..
24/10/202307:01BWArcturus Therapeutics to Attend Upcoming Investor &..
04/10/202323:30BWArcturus Therapeutics Joint Venture mRNA Manufacturing..
27/9/202306:06EDGAR2Form 8-K - Current report
26/9/202322:30BWArcturus Therapeutics and Cystic Fibrosis Foundation Extend..
19/9/202322:30BWStudy Shows Novel sa-mRNA Vaccines Offer Robust, Broad,..
05/9/202322:30BWArcturus Therapeutics and CSL Announce European Medicines..
17/8/202322:30BWArcturus Therapeutics to Attend Upcoming Investor..
14/8/202323:00BWArcturus Therapeutics Joint Venture mRNA Manufacturing..
08/8/202307:02EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/8/202306:23EDGAR2Form 8-K - Current report
08/8/202306:20EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
08/8/202306:01BWArcturus Therapeutics Announces Second Quarter 2023..
04/8/202306:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
04/8/202306:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/7/202306:01BWArcturus Therapeutics to Report Second Quarter 2023..
14/7/202321:53EDGAR2Form 8-K - Current report
30/6/202322:28EDGAR2Form 8-K - Current report
01/6/202322:30BWArcturus Therapeutics Receives U.S. FDA Fast Track..
10/5/202306:01BWArcturus Therapeutics Announces First Quarter 2023 Financial..
26/4/202322:30BWArcturus Therapeutics to Report First Quarter Financial..
29/3/202307:01BWArcturus Therapeutics Announces Fourth Quarter 2022..
08/3/202300:00BWArcturus Therapeutics to Report Fourth Quarter and Full Year..
07/2/202300:30BWArcturus Therapeutics to Attend Upcoming Investor..
01/2/202300:30BWArcturus Therapeutics Announces Clinical Trial Application..
20/12/202200:30BWArcturus Therapeutics to Present at the 41st Annual J.P...
14/12/202200:30BWArcturus Appoints John Markels, Ph.D. to its Board of..
13/12/202200:30PRNUSCSL Announces Closing of Global Collaboration and Licensing..

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com